Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
  • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
  • C07D239/52—Two oxygen atoms
  • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
  • C07F7/02—Silicon compounds
  • C07F7/08—Compounds having one or more C—Si linkages
  • C07F7/0803—Compounds with Si-C or Si-Si linkages
  • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
  • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Engineering & Computer Science (AREA)
• Pain & Pain Management (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=62685028

Family Applications (1)

Country Status (23)

Families Citing this family (3)

Family Cites Families (8)

• 2017
  • 2017-05-31 WO PCT/JP2017/020322 patent/WO2018220762A1/ja not_active Ceased
• 2018
  • 2018-05-30 TW TW113135307A patent/TW202502754A/zh unknown
  • 2018-05-30 TW TW112129778A patent/TWI860022B/zh active
  • 2018-05-30 TW TW107118471A patent/TWI808974B/zh active
  • 2018-05-31 AU AU2018277949A patent/AU2018277949B2/en active Active
  • 2018-05-31 JP JP2019535398A patent/JP6739653B2/ja active Active
  • 2018-05-31 PL PL18732930T patent/PL3630729T3/pl unknown
  • 2018-05-31 SI SI201830499T patent/SI3630729T1/sl unknown
  • 2018-05-31 US US16/471,998 patent/US10800758B2/en active Active
  • 2018-05-31 DK DK18732930.5T patent/DK3630729T3/da active
  • 2018-05-31 EP EP18732930.5A patent/EP3630729B1/en active Active
  • 2018-05-31 KR KR1020257014452A patent/KR20250065436A/ko not_active Ceased
  • 2018-05-31 LT LTEPPCT/JP2018/020997T patent/LT3630729T/lt unknown
  • 2018-05-31 EA EA201992831A patent/EA038907B1/ru unknown
  • 2018-05-31 HR HRP20211913TT patent/HRP20211913T1/hr unknown
  • 2018-05-31 KR KR1020197037748A patent/KR102688531B1/ko active Active
  • 2018-05-31 KR KR1020247024724A patent/KR20240116588A/ko not_active Ceased
  • 2018-05-31 PT PT187329305T patent/PT3630729T/pt unknown
  • 2018-05-31 MY MYPI2019006936A patent/MY199251A/en unknown
  • 2018-05-31 ES ES18732930T patent/ES2901452T3/es active Active
  • 2018-05-31 WO PCT/JP2018/020997 patent/WO2018221667A1/en not_active Ceased
  • 2018-05-31 HU HUE18732930A patent/HUE056942T2/hu unknown
  • 2018-05-31 CN CN201880030366.XA patent/CN110603248B/zh active Active
  • 2018-05-31 MX MX2019014384A patent/MX391338B/es unknown
• 2019
  • 2019-11-12 IL IL270579A patent/IL270579B2/en unknown
  • 2019-11-14 SA SA519410563A patent/SA519410563B1/ar unknown
  • 2019-11-22 PH PH12019502639A patent/PH12019502639A1/en unknown
• 2020
  • 2020-09-02 US US17/010,182 patent/US20200399245A1/en not_active Abandoned
• 2021
  • 2021-12-13 CY CY20211101091T patent/CY1125073T1/el unknown
• 2022
  • 2022-12-30 US US18/091,790 patent/US20230138411A1/en not_active Abandoned
• 2025
  • 2025-08-08 US US19/294,534 patent/US20250361224A1/en active Pending

Also Published As

Similar Documents